Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 309 across all filing types
Latest filing 2025-10-30 Regulatory Filings
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
[기재정정]생산중단(자회사의 주요경영사항)
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement regarding the production suspension and resumption of certain pharmaceutical products by a subsidiary company. It includes details such as dates of production suspension and resumption, reasons for suspension (regulatory violations), financial impact in terms of sales, and board resolution dates. The document is relatively short (2417 characters) and focuses on operational and regulatory updates rather than financial results or detailed reports. It does not contain financial statements or detailed financial analysis. It is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or earnings release. It is a regulatory announcement about a significant operational event affecting the company and its subsidiary. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-30 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 95% confidence The document is a disclosure about a significant business event related to a subsidiary company, specifically the application for additional indication approval for a pharmaceutical product (Fexuclue) by the regulatory authority (Korean Ministry of Food and Drug Safety). It includes detailed clinical trial information, dates, and regulatory submission details. The document is an announcement of a material event relevant to investors regarding regulatory approval and clinical trial progress, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis. It is a regulatory announcement about a significant corporate event affecting investment decisions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-27 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is titled '주식등의 대량보유상황보고서(약식)' which translates to 'Report on Large Shareholding Status (Abbreviated)'. It details the shareholding changes of a major shareholder, specifically the National Pension Service (국민연금공단), including the number of shares held, changes in holdings, and related legal confirmations. The document references specific legal provisions related to large shareholding disclosures under capital market laws. It does not contain financial statements, earnings data, or management commentary. Instead, it is a notification/report of significant share ownership changes. This matches the definition of 'Major Shareholding Notification' (Code: MRQ). The document length is over 6,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the correct classification is MRQ with high confidence.
2025-10-01 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure filed by Daewoong regarding a material business event: the re-submission of a product license application (Nabota) to the Chinese NMPA. It details the clinical trial results, the regulatory status, and the strategic rationale for the re-submission. As it is a specific regulatory announcement of a material event that does not fit into categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2025-09-15 Korean
투자판단관련주요경영사항(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding the approval of a new drug (Fexuclue) by the Chinese NMPA. It is a specific corporate disclosure of a material event (major management matter) filed with the Korea Exchange (KRX). Since it does not fit into specific categories like financial reports, dividends, or M&A, and is a standard regulatory disclosure of a business development, it is classified as a Regulatory Filing (RNS).
2025-09-05 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report) which is the Korean equivalent of an Annual Report (10-K). It contains comprehensive financial data, management discussion and analysis (MDA), corporate governance details, and business operations summaries for the fiscal year ending 2024.12.31. It is a formal regulatory filing submitted to the financial authorities. FY 2024
2025-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.